Alpha Tau Medical Confirms No Direct Exposure to Silicon Valley Bank

Alpha Tau Medical Announces Full Year 2022 Financial Results and Provides Corporate Update

Treatment of 1st two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial

Receipt of Increased Radioactive License and Final Pre-Clinical Laboratory Regulatory Approval

Health Canada Authorization for Alpha DaRT Clinical Trial for the Treatment of Liver Metastases

Alpha Tau to Present at Biotech Showcase and Participate in LifeSci Advisors Corporate Access Event

Alpha Tau Medical Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Alpha Tau to Present at Upcoming November Investor Conferences

Alpha Tau Announces Multiple Corporate Updates Ahead of 2022 Annual Meeting of the American Society

Acceptance in Major Peer-Reviewed Journals of two Landmark Pre-Clinical Studies